In 2012, the company's leading drug Diovan will lose patent protection, creating a massive gap in sales as the drug represents close to 10% of Novartis' total sales.Expectations for switching patients to Tasigna from Gleevec before Gleevec's 2015 patent expiration may prove too optimistic, as
Mergers entail a great deal of risk, and the combined firm may not realize anticipated synergies.Uncertainty surrounding the patent life of Ultram ER, as well as the size and timing of a replacement product, makes future cash flows a bit of a moving target.Competition could heat up in any of the
Glaxo's decision to divert marketing resources away from Coreg CR to its diabetes drug Avandia, which was linked to cardiovascular events, has stunted the drug's uptake and jeopardized Flamel's primary royalty stream.Partnerships for insulin, herpes, and acid reflux drug candidates have gotten the
Despite its profitable EDT business , Elan's overall performance depends heavily on Tysabri ; the drug accounted for 65 % of Elan's revenue in 2009 , and the growing incidence of PML cases as well as potential new oral competition could weigh on the drug's potential . Although J & J's backing for
We may slightly reduce our fair value estimate for Biovail BVF following a disappointing gross margin in the third quarter. We had expected a significant boost, as a percentage of sales, with the acquisition of Wellbutrin XL. Instead, the gross margin was down because of the sell-through of
Despite its profitable EDT business, Elan's overall performance is heavily dependent on Tysabri; the drug accounted for 56% of Elan's revenue in 2008, and recent PML cases have investors concerned that the drug's success may be short-lived.Although J&J's backing for Alzheimer's immunotherapy
We're maintaining Hospira's HSP fair value estimate following strong third-quarter earnings as well as a small boost to management's earnings per share projection for 2009. The company's quarterly sales surged past the billion dollar mark on the launch of generic oncolytic oxaliplatin, for which ...
We're keeping our fair value estimate intact after reviewing Flamel Technologies' FLML progress in recent months. The firm's Medusa platform continues to generate attention and garner small licensing payments; Flamel recently signed a deal with Baxter International BAX to develop controlled-release
Alkermes ALKS announced a change in leadership on Friday. CEO David Broecker has resigned and former CEO and current board chairman Richard Pops will assume his role. The firm gave no reason for Broecker's departure, and we would like to dig into the reasoning further. While we haven't heard any ...